Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Other Pharmacy Practice (3)
- Benzamid (1)
- Community Pharmacy (1)
- Cystic fybrosis (1)
- Department of Psychiatry (1)
-
- Drug abuse (1)
- Drug therapy (1)
- Health Risks (1)
- Household items (1)
- Huffing (1)
- Inhalants (1)
- Isoniazid (1)
- Latent Tuberculosis Infection (1)
- Medication Adherence (1)
- Metabolism (1)
- Metoclopramide (1)
- Nonprescription drug abuse (1)
- OTC drugs (1)
- Over-the-counter medications (1)
- Purpura (1)
- Signs and symptoms (1)
- Sniffing (1)
- Travel (1)
- Travel Medicine (1)
- Travelers Diseases (1)
- Treatment (1)
- Vaccines (1)
Articles 1 - 6 of 6
Full-Text Articles in Chemicals and Drugs
Isoniazid Completion Rates For Latent Tuberculosis Infection Among College Students Managed By A Community Pharmacist, Karl Hess, Jeffery Goad, Joanne Wu, Kathleen Johnson
Isoniazid Completion Rates For Latent Tuberculosis Infection Among College Students Managed By A Community Pharmacist, Karl Hess, Jeffery Goad, Joanne Wu, Kathleen Johnson
Jeff Goad
Objective: The authors' objective was to document 9-month and previously recommended 6-month treatment completion rates for latent tuberculosis infection (LTBI) in a pharmacist-managed LTBI clinic in a community pharmacy oil a college Campus. and to describe patient characteristics. Participants: Participants were university Students diagnosed with LTBI. Methods: The authors conducted a retrospective review, of pharmacy records from 2000 to 2006. Main outcome measures included 6-month and 9-month LTBI treatment completion rates, total isoniazid (INH) tablets taken. characteristics of completers versus noncompleters. average time to treatment completion, and reported adverse drug events. Results: The 9-month completion rate was 59%, and the …
Vaccine-Preventable Diseases In Travelers, Edith Mirzaian, Jeffery Goad, Ani Amloian, Fady Makar
Vaccine-Preventable Diseases In Travelers, Edith Mirzaian, Jeffery Goad, Ani Amloian, Fady Makar
Jeff Goad
Travel to the developing world is increasing among those from developed countries, placing them at risk for vaccine preventable and non-vaccine preventable diseases. From 2007-2011, the GeoSentinel Network reported 737 returned travelers with a vaccine preventable disease. While it is essential that clinicians use vaccines when available for a disease of risk, they should also be aware that the vast majority of diseases acquired by travelers are non-vaccine preventable. The vaccine preventable diseases can be divided into routine travel vaccines, special travel vaccines and routine vaccines used for travel. The routine travel vaccines include Hepatitis A and B, typhoid; special …
Non-Prescription And Household Substances Of Abuse, J. Mallari, L. Nguyen, Jeffery Goad
Non-Prescription And Household Substances Of Abuse, J. Mallari, L. Nguyen, Jeffery Goad
Jeff Goad
"Reasons for abuse of [household products and over-the-counter (OTC) medications] can vary widely depending on the type of product used. Because these items can be readily found in pharmacies and stores, it is important for pharmacists to become familiar with the signs and symptoms of abuse, and street names by which these agents are known (see Table 1). Pharmacists, especially in the community setting, may be able to identify patterns of abuse since they are in contact with patients more frequently than other healthcare providers."
Reversible Nonthrombocytopenic Palpable Purpura Associated With Metoclopramide, Jeffery Goad
Reversible Nonthrombocytopenic Palpable Purpura Associated With Metoclopramide, Jeffery Goad
Jeff Goad
OBJECTIVE: To report a case of reversible nonthrombocytopenic palpable purpura associated with metoclopramide. CASE SUMMARY: A 72-year-old white man was admitted for worsening palpable purpura over a two-day period. Two days prior to admission, metoclopramide 10 mg orally three times per day was started for a gastrointestinal condition. Upon admission, all drugs were continued except metoclopramide. Over the next two days, the purpura began to resolve. Platelet count was within normal limits on admission and the patient developed no serious consequences because of the purpura. DISCUSSION: According to the literature, reversible nonthrombocytopenic palpable purpura has not been previously reported with …
A Double-Blind, Randomized, Placebo-Controlled Trial Of Adjunctive Ramelteon For The Treatment Of Insomnia And Mood Stability In Patients With Euthymic Bipolar Disorder, Edward Norris, Karen Burke, Julia Correll, Ken Zemanek, Joel Lerman, Ralph Primelo, Michael Kaufmann
A Double-Blind, Randomized, Placebo-Controlled Trial Of Adjunctive Ramelteon For The Treatment Of Insomnia And Mood Stability In Patients With Euthymic Bipolar Disorder, Edward Norris, Karen Burke, Julia Correll, Ken Zemanek, Joel Lerman, Ralph Primelo, Michael Kaufmann
Edward R Norris MD, FAPA, FAPM
No abstract provided.
Pharmacological Modulation Of Cgmp Levels By Phosphodiesterase 5 Inhibitors As A Therapeutic Strategy For Treatment Of Respiratory Pathology In Cystic Fibrosis., Hongwei Yu, Jens Poschet, Graham Timmons, Jennifer Taylor-Cousar, Wojciech Ornatowski, Joseph Fazio, Elizabeth Perkett, Kari Wilson, Hugo De Jonge, Vojo Deretic
Pharmacological Modulation Of Cgmp Levels By Phosphodiesterase 5 Inhibitors As A Therapeutic Strategy For Treatment Of Respiratory Pathology In Cystic Fibrosis., Hongwei Yu, Jens Poschet, Graham Timmons, Jennifer Taylor-Cousar, Wojciech Ornatowski, Joseph Fazio, Elizabeth Perkett, Kari Wilson, Hugo De Jonge, Vojo Deretic
Hongwei Yu
The CFTR gene encodes a chloride channel with pleiotropic effects on cell physiology and metabolism. Here, we show that increasing cGMP levels to inhibit epithelial Na(+) channel in cystic fibrosis (CF) respiratory epithelial cells corrects several aspects of the downstream pathology in CF. Cell culture models, using a range of CF cell lines and primary cells, showed that complementary pharmacological approaches to increasing intracellular cGMP, by elevating guanyl cyclase activity though reduced nitric oxide, addition of cell-permeable cGMP analogs, or inhibition of phosphodiesterase 5 corrected multiple aspects of the CF pathological cascade. These included correction of defective protein glycosylation, bacterial …